-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 2 Recently, Shandong New Times Pharmaceutical's application for the imitation of Epirubicin Hydrochloride Injection Type 4 has entered the administrative examination and approval stage.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
Figure 1: The status of products approved by Shandong New Times Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Figure 2: The sales of epirubicin (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Epirubicin is mainly suitable for the treatment of malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia.
At present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
At present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
Figure 3: Evaluation of the consistency of epirubicin
Source: One-click search on Mi Nei.
com
com
Hisun Pharmaceutical’s supplementary application for the consistency evaluation of epirubicin hydrochloride for injection was approved in March 2021.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Source: Company announcement, Minet database
Medical Network News, June 2 Recently, Shandong New Times Pharmaceutical's application for the imitation of Epirubicin Hydrochloride Injection Type 4 has entered the administrative examination and approval stage.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
Figure 1: The status of products approved by Shandong New Times Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Figure 2: The sales of epirubicin (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Epirubicin is mainly suitable for the treatment of malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia.
At present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
At present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
Figure 3: Evaluation of the consistency of epirubicin
Source: One-click search on Mi Nei.
com
com
Hisun Pharmaceutical’s supplementary application for the consistency evaluation of epirubicin hydrochloride for injection was approved in March 2021.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Source: Company announcement, Minet database
Medical Network News, June 2 Recently, Shandong New Times Pharmaceutical's application for the imitation of Epirubicin Hydrochloride Injection Type 4 has entered the administrative examination and approval stage.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
After approval, it is expected to become the first company to review the product.
Epirubicin is the TOP2 variety of cytotoxic antibiotics and related substances in anti-tumor drugs.
Products on the market include powder injections and injections.
In March this year, Hisun Pharmaceutical's powder injections were approved and won the first review.
Figure 1: The status of products approved by Shandong New Times Pharmaceutical
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Figure 2: The sales of epirubicin (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Epirubicin is mainly suitable for the treatment of malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, leukemia.
At present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
Hospital hospital hospitalAt present, there are two major products, epirubicin hydrochloride injection and epirubicin hydrochloride for injection, in the domestic market.
In 2018, they were used in urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
) The total terminal sales have exceeded 1 billion yuan, and the trend has been declining in the past two years.
The total sales in 2020 will be around 800 million yuan.
Figure 3: Evaluation of the consistency of epirubicin
Source: One-click search on Mi Nei.
com
com
Hisun Pharmaceutical’s supplementary application for the consistency evaluation of epirubicin hydrochloride for injection was approved in March 2021.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Shandong New Times Pharmaceutical’s epirubicin hydrochloride injection was declared to be marketed according to four types of generic applications.
If approved, it will be considered The same comment.
From the perspective of product situation, Shandong New Times Pharmaceuticals has already had the production approval of epirubicin hydrochloride for injection.
If the injection can be successfully approved, it will greatly help the company's sales performance in this product.
Source: Company announcement, Minet database
